The Biotechnology Innovation Organization (BIO) today applauds the Senate passage of the Pandemic and All-Hazards Preparedness and Advancing Innovation (PAHPAI) Act (S. 1379). The legislation would re-authorize critical federal biodefense programs and agencies, including the BioShield Special Reserve Fund (SRF), the Biomedical Advanced Research and Development Authority (BARDA), and the Strategic National Stockpile (SNS). The legislation also authorizes funding for pandemic influenza product development and procurement for the first time.
The following statement may be attributed to BIO President and CEO Jim Greenwood:
Over the past 16 years, federal biodefense programs have spurred the creation of dozens of medical countermeasures by the biotechnology industry, greatly improving our nations preparedness to respond to the many known and unknown chemical, biological, radiological and nuclear threats (CBRN) facing our nation, said BIO President and CEO Jim Greenwood. But as the number and scale of threats continues to grow, these programs are needed now more than ever.”
This bipartisan legislation will provide critical flexibility and predictability for government agencies and their private sector partners by authorizing increased, multi-year funding for the BioShield Special Reserve Fund and by empowering BARDA to better address CBRN threat agents, pandemic influenza, emerging infectious diseases, and antimicrobial resistance. The investments in preparedness and medical countermeasure development enabled by this legislation will save lives, enhance our response efforts, and be more cost effective in an emergency.
I thank Senators Richard Burr, Bob Casey, as well as HELP Committee Chairman Lamar Alexander and Ranking Member Patty Murray for their bipartisan leadership crafting and advancing this critical legislation. In addition, I applaud Senator Tammy Baldwin for her championship of pandemic influenza preparedness, which will significantly bolster our nations ability to respond to the emergence of novel influenza viruses.
BIO is the world’s largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the worlds largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIOtechNOW is BIO’s blog chronicling innovations transforming our world and the BIO Newsletter is the organizations bi-weekly email newsletter. Subscribe to the BIO Newsletter.
Upcoming BIO Events
BIO International Convention June 3-6, 2019 Philadelphia, PA
July 8-11, 2019
Des Moines, Iowa